Metastatic Disease Clinical Trials in Shenzhen, Guangdong
2 recruitingShenzhen, Guangdong, China
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)Metastatic DiseaseUnresectable Locally Advanced
Beijing Biotech42 enrolled1 locationNCT07627711
Recruiting
Phase 1Phase 2
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech42 enrolled1 locationNCT07480928